Mitomycin C and cisplatin enhanced the antitumor activity of p53-expressing adenovirus in cervical cancer cells

Cancer Invest. 2001;19(4):360-8. doi: 10.1081/cnv-100103131.

Abstract

This study investigated the enhanced antitumor activity of Ad5-p53 in combination with mitomycin C (MMC) or cisplatin (DDP) in cervical cancer cell lines SiHa and C-33A. MMC and DDP inhibited the growth of SiHa and C-33A cells in a dose-dependent manner, and the combination of MMC or DDP with Ad5-p53 showed a stronger growth inhibition than those treated with either Ad5-p53, MMC, or DDP alone. As evidenced by the formation of the approximately 200 bp DNA ladder and the appearance of sub-G1 peak, both MMC and DDP induced apoptosis in cervical cancer cells. Western blot analysis of p53 showed that MMC/DDP did not induce the increase of p53 protein in SiHa cells nor the increase of the cellular and nuclear p53 protein in Ad5-p53 transfected Saos-2 cells. Taken together, these results suggested that the combination of Ad5-p53 and MMC/DDP may serve as an effective therapeutic regime for human cervical cancer treatment.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenoviruses, Human / genetics*
  • Antineoplastic Agents, Alkylating / pharmacology*
  • Apoptosis / drug effects
  • Bone Neoplasms / pathology
  • Carcinoma, Squamous Cell / pathology*
  • Cell Cycle / drug effects
  • Cisplatin / pharmacology*
  • Dose-Response Relationship, Drug
  • Drug Synergism
  • Female
  • Genes, p53*
  • Genetic Therapy
  • Genetic Vectors / genetics*
  • Humans
  • Mitomycin / pharmacology*
  • Osteosarcoma / pathology
  • Recombinant Fusion Proteins / physiology
  • Transfection
  • Tumor Suppressor Protein p53 / genetics
  • Tumor Suppressor Protein p53 / physiology
  • Uterine Cervical Neoplasms / pathology*

Substances

  • Antineoplastic Agents, Alkylating
  • Recombinant Fusion Proteins
  • Tumor Suppressor Protein p53
  • Mitomycin
  • Cisplatin